Cancer Pathogenesis and Therapy (Jul 2025)
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
- Yutong Wang,
- Qiming Xu,
- Yuan Li,
- Yongbin Su,
- Ling Wang,
- Xiaoquan Wang,
- Jian Ge,
- Hongmei Jing,
- Yuxing Guo,
- Yalin Chen,
- Xianan Li,
- Jun-ling Zhuang,
- Jing Tan,
- Xiaobo Wang,
- Liye Zhong,
- Jun Luo,
- Peng Zhao,
- Shengjin Fan,
- Jinhai Ren,
- Haiping Yang,
- Heng Mei,
- Chunyan Sun,
- Chunrui Li,
- Xuemei Sun,
- Xuechun Lu,
- Guangxun Gao,
- Zeping Zhou,
- Yaozhu Pan,
- Ying Sun,
- Zhang Hong,
- Zhiqiang Liu,
- Yanping Ma,
- Yi Wang,
- Wei Sun,
- Jian Hou,
- Jianqing Mi,
- Wenming Chen,
- Xiaobing Huang,
- Bingzong Li,
- Rong Fu,
- Jumei Shi,
- Xuehong Ran,
- Fuling Zhou,
- Aili He,
- Min Mao,
- Zhen Cai,
- Nan Li,
- Meng Xu,
- Xiaojing Yan,
- Wei Yang,
- Gang An,
- Lihua Gong,
- Lichao Sun,
- Zhihong Li,
- Tang Liu,
- Yanjuan He,
- Junqiang Yin,
- Yao Liu,
- Weifeng Liu,
- Li Bao
Affiliations
- Yutong Wang
- Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China
- Qiming Xu
- Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China
- Yuan Li
- Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China
- Yongbin Su
- Department of Radiology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China
- Ling Wang
- Department of Radiology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China
- Xiaoquan Wang
- Department of Rehabilitation, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China
- Jian Ge
- Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China
- Hongmei Jing
- Department of Hematology, Peking University Third Hospital, Beijing 100191, China
- Yuxing Guo
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China
- Yalin Chen
- Department of Radiotherapy, Peking University People's Hospital, Beijing 100044, China
- Xianan Li
- Department of Radiotherapy, Peking University People's Hospital, Beijing 100044, China
- Jun-ling Zhuang
- Department of Hematology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
- Jing Tan
- Department of Hematology, The Third People's Hospital of Chengdu, Chengdu, Sichuan 610031, China
- Xiaobo Wang
- Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, China
- Liye Zhong
- Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, China
- Jun Luo
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China
- Peng Zhao
- Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, China
- Shengjin Fan
- Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, China
- Jinhai Ren
- Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, China
- Haiping Yang
- Department of Hematology, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, Henan 471000, China
- Heng Mei
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
- Chunyan Sun
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China
- Chunrui Li
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China
- Xuemei Sun
- Division of Hematology, Department of Medicine, Jiangsu Provincial Traditional Chinese Medical Hospital, Nanjing, Jiangsu 210023, China
- Xuechun Lu
- Department of Hematology, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China
- Guangxun Gao
- Department of Hematology, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi 710032, China
- Zeping Zhou
- Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650504, China
- Yaozhu Pan
- Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou, Gansu 730050, China
- Ying Sun
- Department of Hematology, Chifeng Municipal Hospital, Chifeng, Nei Monggol 024000, China
- Zhang Hong
- Department of Hematology, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong 271000, China
- Zhiqiang Liu
- Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China
- Yanping Ma
- Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
- Yi Wang
- Department of Hematology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China
- Wei Sun
- Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
- Jian Hou
- Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
- Jianqing Mi
- Department of Hematology, Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Wenming Chen
- Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China
- Xiaobing Huang
- Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China
- Bingzong Li
- Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China
- Rong Fu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
- Jumei Shi
- Department of Hematology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200123, China
- Xuehong Ran
- Department of Hematology, Weifang People's Hospital, The First Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261041, China
- Fuling Zhou
- Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China
- Aili He
- Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China
- Min Mao
- Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang Uygur Autonomous Region 830001, China
- Zhen Cai
- Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China
- Nan Li
- Department of Orthopedics, Forth Medical Center of PLA General Hospital 100048, Beijing, China
- Meng Xu
- Department of Orthopedics, Forth Medical Center of PLA General Hospital 100048, Beijing, China
- Xiaojing Yan
- Department of Hematology, First Hospital of China Medical University, Shenyang, Liaoning 110001, China
- Wei Yang
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110055, China
- Gang An
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
- Lihua Gong
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Lichao Sun
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Zhihong Li
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
- Tang Liu
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
- Yanjuan He
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, China
- Junqiang Yin
- Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China
- Yao Liu
- Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing 400044, China
- Weifeng Liu
- Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China; Corresponding author: Department of Orthopedic Oncology, Beijing, Jishuitan Hospital, Capital Medical University, No. 31 East Xinjiekou Street, Xicheng District, Beijing 100035, China.
- Li Bao
- Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100031, China; Corresponding author: Department of Hematology, Beijing, Jishuitan Hospital, Capital Medical University, No. 31 East Xinjiekou Street, Xicheng District, Beijing 100035, China.
- Journal volume & issue
-
Vol. 3,
no. 4
pp. 280 – 292
Abstract
This consensus on multiple myeloma-related bone diseases (MBDs) underscores the importance of a multidisciplinary approach that encompasses hematology, radiology, orthopedics, and additional specialties to tackle its intricate challenges. MBD, a prevalent and debilitating complication of multiple myeloma, leads to bone pain, fractures, and skeletal-related events (SREs), which profoundly impact patients’ quality of life. The guidelines offer a thorough framework for diagnosis, treatment, and continual assessment, emphasizing early detection and consistent monitoring using imaging techniques such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI). Treatment strategies prioritize the careful application of anti-myeloma agents, bisphosphonates, and denosumab to minimize bone loss and decrease SRE risk, complemented by surgical and radiotherapy interventions for structural or pain-related issues. Supportive care measures, including pain management, rehabilitation, nutritional support, and dental evaluations, play a crucial role in enhancing patient outcomes and preserving quality of life. This consensus advocates a standardized, evidence-based approach to managing MBD, ensuring comprehensive and coordinated care for patients.
